First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis.
Saved in:
| Title: | First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis. |
|---|---|
| Authors: | Li, Huijuan1,2,3 (AUTHOR), Liang, Xueyan2 (AUTHOR), Qin, Shiran3 (AUTHOR), Chen, Xiaoyu2,3 (AUTHOR), Huang, Liju2 (AUTHOR) 395154496@qq.com, Li, Yan3 (AUTHOR) yli@gxams.org.cn |
| Source: | PLoS ONE. 5/16/2025, Vol. 20 Issue 5, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 19326203 |
|---|---|
| DOI: | 10.1371/journal.pone.0324057 |
